Promoter holding
64.27%
PP
Piramal Pharma Limited - Due diligence report
A 360° intelligence report on Piramal Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Piramal Pharma — 360° Intelligence Report
Generated from MCA filings & public records84/100
Trust Score
Low Risk
Piramal Pharma is assessed as Low Risk with a Trust Score of 84/100. Piramal Pharma is an active public limited indian non-government company incorporated in 2020, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 19 Jul 2026 from the latest processed filings. Piramal Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
- Moderate gearing (D/E 38%).
- Profitable - internal accruals available.
- Externally credit-rated (AA).
Charges position: 16 open (2,430.00 cr) · 4 satisfied (1,000.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Idbi Trusteeship Services Limited | 11 | 48.0 cr |
| Others | 4 | 48.0 cr |
| The Hongkong And Shanghai Banking Corporation Limited | 2 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
| Citi Bank N.A. | 1 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 4 court forum(s).
- Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
- 19 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NANDINI AJAY PIRAMAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PETER D DEYOUNG | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NATHALIE ANN LEITCH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIVEK VALSARAJ | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRIDHAR GORTHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAIRAJ MANOHAR PURANDARE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TANYA SMILEY DCOSTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PETER ANDREW STEVENSON | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIBHA PAUL RISHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMIT JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIVEK VALSARAJ | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMADORAI SUBRAMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
3
Capital events
-
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Ash Stevens Llc | Subsidiary Company | 74.00% |
| Pel Healthcare Llc | Subsidiary Company | 74.00% |
| Pel Pharma Inc. | Subsidiary Company | 74.00% |
| Piramal Critical Care B.v. | Subsidiary Company | 74.00% |
| Piramal Critical Care Deutschland Gmbh | Subsidiary Company | 74.00% |
| Piramal Critical Care Inc. | Subsidiary Company | 74.00% |
| Piramal Critical Care Italia S.p.a. | Subsidiary Company | 74.00% |
| Piramal Critical Care Limited | Subsidiary Company | 74.00% |
| Piramal Critical Care Pty. Ltd | Subsidiary Company | 74.00% |
| Piramal Critical Care Single Member P.c. | Subsidiary Company | 74.00% |
Key managerial personnel: NANDINI AJAY PIRAMAL (Whole-time director) · PETER D DEYOUNG (Whole-time director) · VIVEK VALSARAJ (CFO) · VIVEK VALSARAJ (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 6 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
16 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 410.08 cr.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 16 open charge(s) of 2,430.00 cr already registered.
- Compliance record supports lending.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Jul 2025
Last AGM held
Annual general meeting
29 Jul 2025
Director ceased
AMIT JAIN
19 May 2025
Charge created
Idbi Trusteeship Services Limited - 300.00 cr
14 May 2025
Director appointed
AMIT JAIN (Director)
Director ceased
NEERAJ BHARADWAJ
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Jan 2025
Director appointed
NATHALIE ANN LEITCH (Director)
12 Dec 2024
Charge created
Idbi Trusteeship Services Limited - 100.00 cr
10 Dec 2024
Charge created
Idbi Trusteeship Services Limited - 200.00 cr
Charge created
Idbi Trusteeship Services Limited - 100.00 cr
10 Sep 2024
Charge created
Idbi Trusteeship Services Limited - 150.00 cr
06 May 2024
Charge satisfied
Idbi Trusteeship Services Limited
12 Feb 2024
Charge created
Idbi Trusteeship Services Limited - 200.00 cr
18 Dec 2023
Charge created
Idbi Trusteeship Services Limited - 130.00 cr
08 Dec 2023
Charge satisfied
Axis Bank Limited
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
12 active director(s) / partner(s); board looks stable and experienced.
19 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
31 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Himadri | L27106WB1987PLC042756 | Kolkata, West Bengal, India |
| Tatachemicals | L24239MH1939PLC002893 | Mumbai, Maharashtra, India |
| Atul | L99999GJ1975PLC002859 | Ahmedabad, Gujarat, India |
| Lauruslabs | L24239AP2005PLC047518 | Anakapalle, Andhra Pradesh, India |
| Bayer India | L24210MH1958PLC011173 | Thane West, Maharashtra, India |
| Pcblltd | L23109WB1960PLC024602 | Kolkata, West Bengal, India |
| Alembic Pharmaceuticals | L24230GJ2010PLC061123 | Vadodara, Gujarat, India |
| Alembic | L26100GJ1907PLC000033 | Baroda, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Piramal Pharma before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Piramal Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Piramal Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Piramal Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Piramal Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Piramal Pharma an active company?
Piramal Pharma has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Piramal Pharma financially healthy?
Piramal Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Piramal Pharma?
Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Piramal Pharma?
Promoters hold the largest single block of equity - exact percentages are in the full report. 12 active director(s) are on record.
Does Piramal Pharma have loans or charges against its assets?
16 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.
Is Piramal Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Piramal Pharma?
Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
